LEVEL A (second line): after confirmed progression on standard first line treatment with
dacarbazine.

LEVEL B (first line): when objective clinical response is observed in LEVEL A, patients
will be included for first line treatment with bevacizumab

Inclusion Criteria:

- Histologically confirmed metastatic (unresectable) melanoma and with progressive
disease

- WHO performance status 0-2

- Age >18 years

- Able to undergo outpatient treatment

- Patients must have clinically and/or radiographically documented measurable disease
according to RECIST criteria

- At least 4 weeks since adjuvant interferon alpha

- Recovered from prior chemotherapy

- Major surgical procedure or significant traumatic injury within 28 days prior to
study treatment start. Biopsy or fine needle aspiration within 5 days prior to study
treatment start. Central venous line placement must be inserted at least 5 days prior
to treatment start.

- Minimum required laboratory data:

Hematology: absolute granulocytes > 1.0 x 109/L platelets > 100 x 109/L Biochemistry:
bilirubin < 1.5 x upper normal limit serum creatinine within normal limits INR < 1.5

- Before patient registration/randomization, written informed consent must be given
according to national and local regulations.

Exclusion Criteria:

- No pregnant or lactating patients can be included

- No prior interferon alpha or IL-2 for metastatic disease

- No more than 1 prior chemotherapy regimen for metastatic disease

- No clinical evidence of coagulopathy

- No brain metastases

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- No history of thrombosis

- No full-dose oral coumarin-derived anticoagulants (INR>1.5) or heparin, thrombolytic
agents, or chronic, daily treatment with aspirin (>325 mg/day)

- No non-steroidal anti-inflammatory medications (those known to inhibit platelet
function at doses used to treat chronic inflammatory diseases)

- No uncontrolled hypertension

- Absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial